Earnings calls

Marksans Pharma concall ledger

Every earnings call for MARKSANS — management tone, guidance, KPIs and promise tracking, quarter by quarter.

MARKSANS · 4 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 06 Feb 2026Call held 06 Feb 2026

MARKSANS Q3 FY26 Earnings Call Transcript & Analysis

Operating Revenue₹754.4 cr+11% YoYEBITDA₹160.7 cr+23% YoYEBITDA Margin21.3%PAT₹113.7 cr+8% YoYGross Margin58.1%

Operating Revenue ₹754 cr (+11% YoY); EBITDA ₹161 cr (+23% YoY); EBITDA Margin 21.3%. Q3 FY26 operating revenue grew by 10.6% YoY to INR 754.4 crores, an all-time high for the quarter.

Read full transcript & analysis

Q2 FY26Published 14 Nov 2025Call held 14 Nov 2025

MARKSANS Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹720.4 cr+12% YoYEBITDA₹144.5 crEBITDA Margin20.1%PAT₹99.1 cr+1% YoYGross Margin57.2%

Revenue ₹720 cr (+12% YoY); EBITDA ₹144 cr; EBITDA Margin 20.1%. Revenue grew 16% QoQ to ₹720.4 crores.

Read full transcript & analysis

Q1 FY26Published 13 Aug 2025Call held 13 Aug 2025

MARKSANS Q1 FY26 Earnings Call Transcript & Analysis

Operating Revenue₹620 cr+5% YoYEBITDA₹100.1 crEBITDA Margin16.1%PAT₹58.2 cr−35% YoYGross Margin57.8%

Operating Revenue ₹620 cr (+5% YoY); EBITDA ₹100 cr; EBITDA Margin 16.1%. Operating revenue grew 5% YoY to INR620 crores.

Read full transcript & analysis

Q4 FY25Published 20 May 2025Call held 20 May 2025

MARKSANS Q4 FY25 Earnings Call Transcript & Analysis

Operating Revenue₹2,623 cr+21% YoYEBITDA₹529 cr+15% YoYEBITDA Margin20.2%PAT₹383 cr+22% YoYGross Margin56.4%

Operating Revenue (FY25) ₹2,623 cr (+20% YoY); EBITDA (FY25) ₹529 cr (+15% YoY); EBITDA Margin (FY25) 20.2%. Operating revenue for FY25 grew 20.5% YoY to ₹2,623 crores.

Read full transcript & analysis